NASDAQ
No price data available for this timeframe.
Stoke Therapeutics, Inc. (STOK) has a free cash flow growth of -98.58% as of Friday, May 29, 2026. This represents a 174.76% decrease compared to its 12-month average of 131.86%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.